What patent(s) cover vorasidenib, and who holds them?
The provided information does not include details about which specific patents cover vorasidenib, the patent numbers, or the assignees/holders. To answer accurately, I’d need a specific patent database entry (e.g., from Google Patents, Lens.org, USPTO, EPO, or WIPO) or the applicant/brand context you’re looking at.
When does the vorasidenib patent expire?
You’ll need the exact patent(s) (and their filing/priority dates) to calculate expiry. Patent life depends on:
- The priority date(s) and jurisdiction (e.g., US vs EP)
- Whether any patent term adjustments/extensions apply
- Whether additional follow-on patents cover specific formulations, dosing regimens, combinations, or crystalline forms
Without the patent numbers or dates, a precise expiry timeline can’t be determined from the provided information.
Are there multiple patents for vorasidenib (primary vs “evergreening” patents)?
Many small-molecule drug programs have:
- A “core” composition-of-matter patent (the earliest key protection)
- Later patents for specific polymorphs, salts, formulations, manufacturing processes, or use/dosing methods
- Patents that may stagger expiry across different regions
But the exact structure for vorasidenib depends on the specific patent family in each jurisdiction, which isn’t included here.
Can generic or biosimilar versions launch before the last vorasidenib patent expires?
For non-biologics like vorasidenib (a small molecule), generic entry is typically driven by patent expiry and any patent “working” before that date. Entry timing can also be affected by:
- “Orange Book” style listings (US) and related litigation
- Country-specific regulatory pathways and patent linkage rules
- Court rulings on patent validity/infringement
However, no vorasidenib-specific regulatory or litigation details are provided here.
Are there ongoing patent challenges or legal disputes about vorasidenib?
Patent disputes are common around oncology small molecules (especially when generics seek approval while patents remain). But there’s no provided information indicating whether vorasidenib patents are currently being challenged, and in which courts or jurisdictions.
What jurisdictions matter most for vorasidenib patents?
Vorasidenib protection may differ across:
- US (USPTO, patent term adjustments, regulatory linkage concepts)
- Europe (EPO/EP, unitary patent possibilities if granted)
- UK, Canada, Japan, China, and others
To map expiry and risk by country, the relevant patent family and grant status in each jurisdiction are required.
What do you need to provide for me to answer precisely?
If you paste any one of the following, I can give a concrete answer about vorasidenib’s patent expiry and coverage:
- A link or patent number (e.g., from Google Patents)
- The applicant/assignee name plus a patent family link
- Filing/priority date and jurisdiction for the specific patent you mean
- Whether you mean the US, EU, UK, or another region
Sources
No sources were provided in the prompt, so I can’t cite any.